Oclacitinib Maleate a new type of JAK inhibitor, also inhibits the function of JAK1 dependent cytokines in some anti allergic, inflammatory and pruritus reactions. The study confirmed that the experimental animals (dogs) were taken orally at a dose of 0.4-0.6mg/kg twice a day, which was safe and effective for the treatment of itching caused by atopic dermatitis, and showed better efficacy than oral glucocorticoids such as prednisolone. During the treatment period, Oratinib can relieve itching within 24 hours, and more than 70% of experimental animals reduced more than 50% of the itching Chemicalbook response on the 7th day. At present, Olatinib has been approved by the US FDA in 2013 to control itching and atopic dermatitis caused by canine allergic dermatitis. However, although Olatinib has a good effect on allergic dermatosis in pet dogs, its scope of action is narrow. On the one hand, it has little effect on the cytokines that do not participate in the activation of JAK1, and on the other hand, its effect on allergic reaction is only to inhibit mast cell degranulation, that is, the release of allergic mediators, which cannot fundamentally and directly block the binding of allergic mediators to related receptors, It can not fundamentally block the occurrence and development of allergic skin diseases.